InvestorsHub Logo
Followers 41
Posts 2864
Boards Moderated 0
Alias Born 01/03/2007

Re: None

Tuesday, 02/08/2011 3:57:38 PM

Tuesday, February 08, 2011 3:57:38 PM

Post# of 60764
HENDERSON, NEVADA--(Marketwire - 02/08/11) - Hiru Corporation's (PINK SHEETS:HIRU - News) (www.hirucorporation.com) main subsidiary Jiangxi Shuangshi Pharmaceutical Co., Ltd. announced that the company representatives conducted investigation into business expansion in Wannian County.

Shuangshi AHP has been focusing on creation of new pharmaceutical products but also on entering Chinese agricultural and animal husbandry market. In a recent development, the company announced that the management started exploring opportunities in Wannian county. The company dispatched its administrators and principals to conduct on-site investigation into acquisition of breeding farms.

China's demand for agricultural products increases with the Chinese economic growth. To give a better view of the growth of China's demand for agricultural products, the company shares the following exemplary statistic: According to China's Ministry of Statistics, the poultry consumption alone increased from 7.5 pounds per capita in 1990, to 18.3 pounds per capita in 2006, a spike of 244% in China's cities, while in the urban areas it increased from 2.75 pounds per capita in 1990 to 7.7 pounds per capita in 2006, an increase of 281%.

Shuangshi AHP creates and grows a solid diversified portfolio of agricultural services on the Chinese market and expects to continue this trend on this growing market.

Hiru Corporation and its main subsidiary Jiangxi Shuangshi Animal Health Products Co. (Shuangshi AHP Co.) focus on the development, manufacturing and marketing of a broad range of veterinary products for the Chinese Agricultural market. The company has established a strong position in the Chinese animal husbandry market and plans to expand and deliver more new products and solutions to this market in the future.

More updates from the company will follow shortly, including updates from the company's R&D arm MindUp BioResearch.